Carnegie Investment Counsel Takes Position in Astera Labs, Inc. $ALAB

Key Points

• Carnegie Investment Counsel purchased a new stake of 60,409 shares in Astera Labs valued at approximately $10.05 million during the fourth quarter.
• Astera Labs beat Q4 estimates with $0.58 EPS (vs. $0.51 consensus) and reported revenue of $270.58 million, up 91.8% year‑over‑year, and guided Q1 2026 EPS to $0.530–$0.540.
• Insiders have been net sellers recently — the CEO sold 157,500 shares and the CFO sold 12,001, with insiders offloading 577,292 shares worth about $69.5 million over the past 90 days.

Carnegie Investment Counsel purchased a new stake in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 60,409 shares of the company's stock, valued at approximately $10,050,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Venturi Wealth Management LLC boosted its holdings in shares of Astera Labs by 2.6% during the 4th quarter. Venturi Wealth Management LLC now owns 3,284 shares of the company's stock valued at $546,000 after acquiring an additional 84 shares during the last quarter. Trilogy Capital Inc. boosted its holdings in shares of Astera Labs by 44.6% during the 4th quarter. Trilogy Capital Inc. now owns 5,351 shares of the company's stock valued at $890,000 after acquiring an additional 1,650 shares during the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Astera Labs by 16.5% during the 4th quarter. Yousif Capital Management LLC now owns 1,740 shares of the company's stock valued at $320,000 after acquiring an additional 246 shares during the last quarter. Greenleaf Trust boosted its holdings in shares of Astera Labs by 10.3% during the 4th quarter. Greenleaf Trust now owns 1,458 shares of the company's stock valued at $243,000 after acquiring an additional 136 shares during the last quarter. Finally, Pacific Point Advisors LLC grew its holdings in shares of Astera Labs by 17.6% in the fourth quarter. Pacific Point Advisors LLC now owns 10,000 shares of the company's stock worth $1,664,000 after acquiring an additional 1,500 shares during the period. Hedge funds and other institutional investors own 60.47% of the company's stock.

Astera Labs Stock Performance

NASDAQ:ALAB opened at $149.05 on Friday. The stock has a 50-day simple moving average of $128.11 and a two-hundred day simple moving average of $155.08. Astera Labs, Inc. has a 52-week low of $52.56 and a 52-week high of $262.90. The firm has a market capitalization of $25.52 billion, a PE ratio of 122.17, a P/E/G ratio of 2.93 and a beta of 1.78.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The business had revenue of $270.58 million during the quarter, compared to analyst estimates of $249.46 million. During the same quarter in the previous year, the company posted $0.37 earnings per share. Astera Labs's revenue for the quarter was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Equities analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on ALAB shares. Royal Bank Of Canada started coverage on Astera Labs in a report on Wednesday, January 14th. They issued an "outperform" rating and a $225.00 price objective for the company. Weiss Ratings lowered Astera Labs from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, February 23rd. Loop Capital started coverage on Astera Labs in a report on Thursday, March 5th. They issued a "buy" rating and a $250.00 price objective for the company. Citigroup started coverage on Astera Labs in a report on Thursday, April 2nd. They issued a "buy" rating and a $200.00 price objective for the company. Finally, Barclays set a $165.00 price objective on Astera Labs in a report on Thursday, January 15th. Fifteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Astera Labs currently has an average rating of "Moderate Buy" and a consensus price target of $199.44.

Insider Transactions at Astera Labs

In other news, CFO Michael Truett Tate sold 12,001 shares of the company's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $1,485,843.81. Following the completion of the transaction, the chief financial officer owned 192,083 shares of the company's stock, valued at $23,781,796.23. This represents a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jitendra Mohan sold 157,500 shares of the company's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $131.58, for a total value of $20,723,850.00. Following the completion of the transaction, the chief executive officer directly owned 4,531,732 shares of the company's stock, valued at approximately $596,285,296.56. This trade represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 577,292 shares of company stock valued at $69,495,249. 12.50% of the stock is owned by corporate insiders.

Astera Labs News Roundup

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Company signals higher growth expectations and investor optimism ahead of Q1 results — investors interpreted the note as confirmation of robust demand and loaded up on shares. Astera Labs (ALAB) Eyes ‘High Double-Digit Growth,’ Soars 27%
• Positive Sentiment: Product/spec and customer wins: reports say a UALink spec upgrade plus new hyperscaler wins, which are material for Astera’s connectivity/bridge products and signal larger TAM and pull‑through for future revenue. Astera Labs (ALAB) Surges Over 13% on UALink Spec Upgrade and Hyperscaler Wins
• Positive Sentiment: Unusual options activity: traders bought ~39,399 call options (≈54% above typical call volume), a bullish signal that likely amplified intraday buying and expectations for upside around upcoming results.
• Positive Sentiment: Analyst/list support: included in recent growth‑stock roundups and cited with strong insider confidence; an aggregated analyst view is an average “Moderate Buy,” reinforcing buy‑side momentum. April 2026's Leading Growth Stocks With Strong Insider Confidence Astera Labs, Inc. NASDAQ: ALAB Given Average Recommendation of "Moderate Buy" by Analysts
• Neutral Sentiment: Short interest reporting showed zero shares — likely a data/reporting artifact and not meaningful short‑pressure information at present, so it doesn’t explain the move.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.